A Phase 1/2 interventional study of Ibrutinib and Carfilzomib in Multiple Myeloma, sponsored by Pharmacyclics LLC.. Completed at 17 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-21.
Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.
Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 31st largest by enrollment, is one of 14 that started in 2013, is one of 28 in phase 1/2, and was the 41st registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Natalie Callander · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States, Australia, Brazil and 5 more countries
Ages 18+
Roswell Park Cancer Institute · Sites in United States
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
By country, each count listing its studies:
carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 45 · Phase 2 78 · Phase 3 15 · Phase 4 2
First in 2005; this study’s year is marked. 14 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 54 across the 113 interventional studies. Of the 67 that completed or were terminated, 46 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 113 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pharmacyclics LLC., one of the names counted as AbbVie. Under that name alone:
Pharmacyclics LLC. is the lead sponsor of 54 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.
40 studies in Multiple Myeloma by AbbVie: 7 open now, 17 under way, 5 of them phase 3. Of 21 finished, 8 (38%) have results posted.
Among the 40 studies in Multiple Myeloma by AbbVie, this one is the 20th largest by enrollment of the 39 interventional ones that give a count, is the only one that started in 2013, is one of 7 in phase 1/2, and was the 10th registered.
AbbVie’s Multiple Myeloma studies by the year they started, since 2005.
18 of the studies testing carfilzomib in Multiple Myeloma that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03729804Phase 3University of ChicagoCarfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) | 2026-12-28 |
| NCT04096066Phase 3Fondazione EMN Italy OnlusA Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant | 2027-09-01 |
| NCT02659293Phase 3University of ChicagoTrial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma | 2027-11 |
| NCT04973605BeOne MedicinesA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | 2026-11 |
| NCT04883242University of WashingtonIsatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | 2026-12-31 |
Add all 18 to your calendar (.ics) → With an account.
Among the 113 studies testing carfilzomib in Multiple Myeloma, from their registry updates:
Among AbbVie’s 40 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
A MULTICENTER PHASE 1/2B STUDY OF THE BRUTON'S TYROSINE KINASE INHIBITOR, IBRUTINIB (PCI-32765), IN COMBINATION WITH CARFILZOMIB (KYPROLIS™) IN SUBJECTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Bruton's tyrosine kinase (Btk) is an enzyme that is present in hematopoietic cells other than T cells and is necessary for downstream signal transduction from various hematopoietic receptors including the B cell receptor as well as some Fc, chemokine, and adhesion receptors, and is crucial for both B cell development and osteoclastogenesis. Although down-regulated in normal plasma cells, Btk is highly expressed in the malignant cells from many myeloma patients and some cell lines. PCI-32765 is a potent and specific inhibitor of Btk currently in Phase 2 and 3 clinical trials. The current study is designed and intended to determine the safety and efficacy of PCI-32765 in combination with carfilzomib (Kyprolis™) with and without dexamethasone in subjects with relapsed or relapsed and refractory multiple myeloma (MM).
Inclusion Criteria:
of MM as defined by at least ONE of the following:
Inclusion Criteria for Phase 2 Sub-study Cohort:
Subject must have received a regimen containing carfilzomib in combination with dexamethasone as their most recent and have:
Achieved less than a partial response (\<PR) following at least 4 cycles and are without evidence of progression disease (PD).
OR
Exclusion Criteria:
Exclusion Criteria for Phase 2 Sub-study Cohort:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ibrutinib PO 560mg + Carfilzomib IV 20/27mg/m2 + Dexamethasone PO 20mg
Drug: Ibrutinib · Drug: Carfilzomib · Drug: Dexamethasone
Ibrutinib PO 560mg + Carfilzomib IV 20/36mg/m2 + Dexamethasone PO 20mg
Drug: Ibrutinib · Drug: Carfilzomib · Drug: Dexamethasone
Ibrutinib PO 840 mg + Carfilzomib IV 20/36 mg/m2 + Dexamethasone PO 20 mg
Drug: Ibrutinib · Drug: Carfilzomib · Drug: Dexamethasone
Overall Response Rate (ORR)
-To evaluate the overall response (ORR) of ibrutinib in combination with carfilzomib and dexamethasone.
Time frame: up to 4 years
Duration of Response (DOR)
The time interval between the date of initial documentation of a response (PR or better) and the date of first documented evidence of progressive disease, death, or date of censoring for the subjects who had not progressed/died. The censoring date was the last adequate tumor assessment date.
Time frame: Up to 4 years
Overall Survival
Time from date of first dose of study treatment to the date of death from any cause
Time frame: Up to 4 years
Progression Free Survival (PFS)
Time from date of first dose of study treatment to the date of first documented evidence of progressive disease, death or date of censoring for the subjects not progressed/died. The censoring date was the last adequate tumor assessment date.
Time frame: Up to 4 years
| Milestone | Cohort 1 (560 mg) | Cohort 2a (560 mg) | Cohort 2b (560 mg) | All RP2D (840 mg) |
|---|---|---|---|---|
| Started | 3 | 5 | 17 | 59 |
| Completed | 3 | 5 | 17 | 59 |
| Not completed | 0 | 0 | 0 | 0 |
-To evaluate the overall response (ORR) of ibrutinib in combination with carfilzomib and dexamethasone.
| Participants | Cohort 1 (560 mg) | Cohort 2a (560 mg) | Cohort 2b (560 mg) | All RP2D (840 mg) |
|---|---|---|---|---|
| Overall Response Rate (ORR) | 2 | 2 | 12 | 42 |
The time interval between the date of initial documentation of a response (PR or better) and the date of first documented evidence of progressive disease, death, or date of censoring for the subjects who had not progressed/died. The censoring date was the last adequate tumor assessment date.
| Months | Cohort 1 (560 mg) | Cohort 2a (560 mg) | Cohort 2b (560 mg) | All RP2D (840 mg) |
|---|---|---|---|---|
| Duration of Response (DOR) | 7.1 (1.2 to 13.0) | 15.3 (5.4 to 15.3) | 9.2 (3.0 to 14.5) | 7.2 (2.7 to 16.6) |
Time from date of first dose of study treatment to the date of death from any cause
| Months | All RP2D (840 mg) |
|---|---|
| Overall Survival | 35.9 (0.9 to 51.8) |
Time from date of first dose of study treatment to the date of first documented evidence of progressive disease, death or date of censoring for the subjects not progressed/died. The censoring date was the last adequate tumor assessment date.
| Months | All RP2D (840 mg) |
|---|---|
| Progression Free Survival (PFS) | 7.4 (4.6 to 10.2) |
Collected over 4 years, 2months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 (560 mg) | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Cohort 2a (560 mg) | 4/5 (80%) | 5/5 (100%) | 5/5 (100%) |
| Cohort 2b (560 mg) | 9/17 (52.9%) | 17/17 (100%) | 17/17 (100%) |
| All RP2D (840 mg) | 22/59 (37.3%) | 59/59 (100%) | 58/59 (98.3%) |
| Event | Cohort 1 (560 mg) | Cohort 2a (560 mg) | Cohort 2b (560 mg) | All RP2D (840 mg) |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 1/3 | 2/5 | 1/17 | 6/59 |
| Atrial FlutterCardiac disorders | 1/3 | 0/5 | 0/17 | 1/59 |
| ConstipationGastrointestinal disorders | 0/3 | 1/5 | 0/17 | 0/59 |
| DiarrhoeaGastrointestinal disorders | 0/3 | 1/5 | 2/17 | 0/59 |
| AstheniaGeneral disorders | 0/3 | 1/5 | 0/17 | 0/59 |
| Clostridium difficile colitisInfections and infestations | 0/3 | 1/5 | 0/17 | 1/59 |
| Gastrointestinal infectionInfections and infestations | 0/3 | 1/5 | 0/17 | 1/59 |
| Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 1/5 | 0/17 | 1/59 |
| Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 1/5 | 0/17 | 0/59 |
| Non - small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 1/5 | 0/17 | 0/59 |
| Event | Cohort 1 (560 mg) | Cohort 2a (560 mg) | Cohort 2b (560 mg) | All RP2D (840 mg) |
|---|---|---|---|---|
| FatigueGeneral disorders | 0/3 | 4/5 | 12/17 | 27/59 |
| DiarrhoeaGastrointestinal disorders | 0/3 | 3/5 | 11/17 | 29/59 |
| AnaemiaBlood and lymphatic system disorders | 1/3 | 3/5 | 6/17 | 24/59 |
| PyrexiaGeneral disorders | 1/3 | 3/5 | 8/17 | 12/59 |
| ChillsGeneral disorders | 0/3 | 3/5 | 1/17 | 7/59 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/3 | 3/5 | 0/17 | 10/59 |
| Peripheral sensory neuropathyNervous system disorders | 0/3 | 3/5 | 3/17 | 13/59 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/3 | 3/5 | 5/17 | 10/59 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/3 | 1/5 | 3/17 | 30/59 |
| HeadacheNervous system disorders | 1/3 | 2/5 | 8/17 | 13/59 |
| Age, Categorical(Participants) | Cohort 1 (560 mg) | Cohort 2a (560 mg) | Cohort 2b (560 mg) | All RP2D (840 mg) | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 0 | 1 | 12 | 33 | 46 |
| >=65 years | 3 | 4 | 5 | 26 | 38 |
| Age, Continuous(years) | Cohort 1 (560 mg) | Cohort 2a (560 mg) | Cohort 2b (560 mg) | All RP2D (840 mg) | Total |
|---|---|---|---|---|---|
| Median | 69.0 ± 1.53 | 72.0 ± 9.21 | 60.0 ± 10.29 | 63.0 ± 9.86 | 63.5 ± 9.88 |
| Sex: Female, Male(Participants) | Cohort 1 (560 mg) | Cohort 2a (560 mg) | Cohort 2b (560 mg) | All RP2D (840 mg) | Total |
|---|---|---|---|---|---|
| Female | 1 | 1 | 11 | 28 | 41 |
| Male | 2 | 4 | 6 | 31 | 43 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 (560 mg) | Cohort 2a (560 mg) | Cohort 2b (560 mg) | All RP2D (840 mg) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 2 | 7 | 10 |
| Not Hispanic or Latino | 2 | 5 | 15 | 51 | 73 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 1 |
| Region of Enrollment(participants) | Cohort 1 (560 mg) | Cohort 2a (560 mg) | Cohort 2b (560 mg) | All RP2D (840 mg) | Total |
|---|---|---|---|---|---|
| United States | 3 | 5 | 17 | 59 | 84 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2013 to primary completion in Mar 2019, 63 months.
Results were first posted in Dec 2021, 2 years 9 months after primary completion.
Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's 63 months is close to that.
Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ibrutinib · Carfilzomib